Reported Earlier, Innovent Receives FDA Fast Track Designation For IBI363, A PD-1/IL-2α Bispecific Antibody, As Monotherapy For Advanced Melanoma
Reported Earlier, Innovent Receives FDA Fast Track Designation For IBI363, A PD-1/IL-2α Bispecific Antibody, As Monotherapy For Advanced Melanoma
據報道，愛文思控股因IBI363（PD-1/IL-2α雙特異性抗體）單藥治療愛文思控股公司的黑色素瘤而獲得FDA快速通道認定。
Reported Earlier, Innovent Receives FDA Fast Track Designation For IBI363, A PD-1/IL-2α Bispecific Antibody, As Monotherapy For Advanced Melanoma
據報道，愛文思控股因IBI363（PD-1/IL-2α雙特異性抗體）單藥治療愛文思控股公司的黑色素瘤而獲得FDA快速通道認定。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。